Profile data is unavailable for this security.
About the company
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
- Revenue in GBP (TTM)167.75m
- Net income in GBP-159.06m
- Incorporated2005
- Employees1.28k
- LocationOxford Nanopore Technologies PLCOxford Science ParkGosling Building, Edmund Halley RoadOXFORD OX4 4DQUnited KingdomGBR
- Websitehttps://www.nanoporetech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| El En SpA | 548.38m | 41.37m | 760.92m | 2.03k | 18.37 | 2.55 | 14.61 | 1.39 | 0.6223 | 0.6223 | 8.25 | 4.49 | 0.9141 | 1.77 | 3.69 | 316,823.50 | 7.02 | 7.43 | 12.89 | 13.52 | 40.03 | 38.83 | 7.68 | 7.63 | 1.19 | -- | 0.1845 | -- | 2.78 | 14.88 | -12.47 | 23.49 | -13.40 | -- |
| GVS SpA | 354.31m | 21.06m | 846.74m | 4.39k | 39.94 | 2.85 | 14.57 | 2.39 | 0.1457 | 0.1457 | 2.44 | 2.05 | 0.4303 | 2.00 | 6.16 | 97,169.86 | 2.56 | 7.35 | 3.25 | 10.82 | 55.12 | 58.74 | 5.94 | 12.44 | 1.03 | 3.98 | 0.5461 | -- | 9.58 | 15.25 | -43.37 | -9.97 | 16.08 | -- |
| ChemoMetec A/S | 45.46m | 15.19m | 906.90m | 173.00 | 59.71 | 14.39 | 52.84 | 19.95 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
| Biotage AB | 152.36m | 18.41m | 916.86m | 675.00 | 49.82 | 3.36 | 29.22 | 6.02 | 3.21 | 3.21 | 26.56 | 47.60 | 0.4312 | 1.59 | 7.22 | 3,155,786.00 | 5.21 | 10.74 | 6.05 | 12.77 | 62.67 | 61.40 | 12.08 | 15.75 | 1.15 | 43.88 | 0.0616 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
| Xvivo Perfusion AB | 53.77m | 14.63m | 1.02bn | 161.00 | 68.85 | 6.85 | 51.70 | 19.01 | 6.58 | 6.58 | 24.07 | 66.13 | 0.3325 | 1.14 | 4.67 | 4,691,194.00 | 9.05 | 1.24 | 9.68 | 1.33 | 74.41 | 73.14 | 27.21 | 4.76 | 4.23 | -- | 0.0117 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| AddLife AB | 717.16m | 8.38m | 1.14bn | 2.36k | 140.51 | 3.21 | 15.15 | 1.59 | 0.9601 | 0.9601 | 82.16 | 42.09 | 0.7625 | 3.50 | 5.58 | 4,351,152.00 | 0.9063 | 5.31 | 1.29 | 8.83 | 37.30 | 36.89 | 1.19 | 5.79 | 0.638 | 1.66 | 0.5146 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Oxford Nanopore Technologies PLC | 167.75m | -159.06m | 1.37bn | 1.28k | -- | 2.17 | -- | 8.16 | -0.187 | -0.187 | 0.197 | 0.662 | 0.2265 | 0.7333 | 2.86 | 135,499.20 | -21.47 | -21.12 | -24.63 | -24.67 | 53.89 | 53.90 | -94.82 | -81.85 | 3.36 | -- | 0.0747 | -- | -14.57 | 39.15 | -69.74 | -- | 8.92 | -- |
| SKAN Group AG | 305.54m | 28.63m | 1.57bn | 1.42k | 55.22 | 10.23 | 38.21 | 5.15 | 1.43 | 1.43 | 15.24 | 7.70 | 0.9179 | 0.6845 | 12.01 | 247,846.50 | 9.03 | 7.56 | 18.78 | 14.95 | 74.07 | 73.24 | 9.84 | 9.63 | 0.5813 | 38.46 | 0.0341 | 24.09 | 15.55 | 118.77 | 38.59 | 35.49 | -- | -- |
| Elekta AB (publ) | 1.30bn | 81.16m | 1.68bn | 4.57k | 21.43 | 2.27 | 10.14 | 1.29 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Embla Medical hf | 661.25m | 54.35m | 1.70bn | 4.00k | 31.42 | 2.75 | 17.45 | 2.57 | 1.13 | 1.13 | 13.76 | 12.95 | 0.5755 | 2.23 | 6.65 | 1,483,676.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Medacta Group SA | 452.38m | 46.72m | 1.99bn | 1.83k | 42.57 | 6.95 | 20.22 | 4.40 | 2.63 | 2.63 | 25.49 | 16.14 | 0.7908 | 0.85 | 5.62 | 294,410.60 | 8.17 | 7.89 | 10.36 | 10.57 | 67.93 | 70.43 | 10.33 | 10.09 | 0.845 | 11.02 | 0.4015 | 17.01 | 16.85 | 13.38 | 2.41 | 0.6937 | 8.32 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 29 Feb 2024 | 71.16m | 7.56% |
| Storebrand Asset Management ASas of 01 Oct 2024 | 35.29m | 3.75% |
| GIC Pte Ltd. (Investment Management)as of 27 Mar 2024 | 25.70m | 2.73% |
| Lansdowne Partners (UK) LLPas of 29 Feb 2024 | 25.70m | 2.73% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 01 Oct 2024 | 14.59m | 1.55% |
| The Vanguard Group, Inc.as of 01 Oct 2024 | 13.53m | 1.44% |
| Aberforth Partners LLPas of 01 Oct 2024 | 11.13m | 1.18% |
| Norges Bank Investment Managementas of 01 Oct 2024 | 10.03m | 1.07% |
| Nikko Asset Management Americas, Inc.as of 30 Jun 2024 | 7.38m | 0.78% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Sep 2024 | 7.23m | 0.77% |
